Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

MacroGenics’ margetuximab meets breast cancer trial endpoint

Margetuximab is designed as an immune-enhancing monoclonal antibody for HER2-positive metastatic breast cancer. Credit: Dr. Cecil Fox/National Cancer Institute/National Institutes of Health.

  • MacroGenics’ margetuximab meets Phase III breast cancer trial endpoint

Go Top